“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...

GSK has applied to the US Food and Drug Administration (FDA) to extend use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults under the age of 50 who are at increased risk of the ...

In June, infectious disease physicians sounded the alarm over the Trump administration overstepping existing, transparent processes for changing vaccine recommendations, particularly pointing to new ...

FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.

The update covers the safety and appropriate timing of vaccinations, screening for osteoporosis, cervical cancer, skin cancer ...

The American College of Gastroenterology has released a 2025 update to its clinical guideline on preventive care in IBD, replacing the previous 2017 version, Medscape reported July 14. This revised ...

Six in 10 U.S. adults think that AI-generated health information is somewhat or very reliable, a survey from the Annenberg Public Policy Center finds. But nearly half (49%) are not comfortable with ...

While most people will clear the virus and get a negative antigen test result within 10 days, some people may keep testing positive for longer than that, experts tell TODAY.com. And if you keep ...

The Centers for Disease Control and Prevention (CDC) recommends that pregnant women receive an RSV vaccine during their third ...

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa's private sector but not yet in public clinics. The country's advisory group on ...